LPII is a leading pharmaceutical isotope industry specializing in the development of brachytherapy devices for therapeutic applications. Based in Kennewick, Washington, they are dedicated to empowering physicians and medical researchers by providing essential radionuclides that have previously been impractical or costly to produce. LPII's core focus is on obtaining FDA clearance for their patented brachytherapy cancer products, which utilize radiation to eliminate cancerous tumors by placing a radioactive isotope inside or next to the treatment area.

Their proposed line of brachytherapy products incorporates innovative technology developed for Battelle Memorial Institute at Pacific Northwest National Laboratory. With the collaboration of esteemed radiochemists, scientists, engineers, and strategic partners, LPII aims to redefine brachytherapy cancer treatments and revolutionize the field of medical isotope technologies. By detecting, managing, and curing human disease, they strive to improve the lives of patients